131 related articles for article (PubMed ID: 27910876)
1. Drug launch curves in the modern era.
Robey S; David FS
Nat Rev Drug Discov; 2017 Jan; 16(1):13-14. PubMed ID: 27910876
[No Abstract] [Full Text] [Related]
2. Did Medicare Induce Pharmaceutical Innovation?
Acemoglu D; Cutler D; Finkelstein A; Linn J
Am Econ Rev; 2006 May; 96(2):103-7. PubMed ID: 29131561
[No Abstract] [Full Text] [Related]
3. No immediate pain relief for the pharmaceutical industry.
Ahlborn H; Henderson S; Davies N
Curr Opin Drug Discov Devel; 2005 May; 8(3):384-91. PubMed ID: 15892254
[TBL] [Abstract][Full Text] [Related]
4. 2004 approvals: the demise of the blockbuster?
Frantz S
Nat Rev Drug Discov; 2005 Feb; 4(2):93-4. PubMed ID: 15756752
[No Abstract] [Full Text] [Related]
5. New drug development in the United States from 1963 to 1999.
Dimasi JA
Clin Pharmacol Ther; 2001 May; 69(5):286-96. PubMed ID: 11371996
[No Abstract] [Full Text] [Related]
6. Biotech drug market steadily expands.
Lawrence S
Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
[No Abstract] [Full Text] [Related]
7. Biopharmaceutical benchmarks--2003.
Walsh G
Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
[No Abstract] [Full Text] [Related]
8. The biotech drug market.
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
[No Abstract] [Full Text] [Related]
9. A merger too far?
Wadman M
Nature; 2007 Mar; 446(7131):15. PubMed ID: 17330017
[No Abstract] [Full Text] [Related]
10. The economics of follow-on drug research and development: trends in entry rates and the timing of development.
DiMasi JA; Paquette C
Pharmacoeconomics; 2004; 22(2 Suppl 2):1-14. PubMed ID: 15660473
[TBL] [Abstract][Full Text] [Related]
11. Prospects for productivity.
Booth B; Zemmel R
Nat Rev Drug Discov; 2004 May; 3(5):451-6. PubMed ID: 15136792
[No Abstract] [Full Text] [Related]
12. Key factors in the rising cost of new drug discovery and development.
Dickson M; Gagnon JP
Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
[No Abstract] [Full Text] [Related]
13. A changing drug supply.
Nature; 2007 Feb; 445(7127):460. PubMed ID: 17268432
[No Abstract] [Full Text] [Related]
14. [Fewer new drugs from drug industry].
Reikvam A
Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3106-7. PubMed ID: 18049505
[No Abstract] [Full Text] [Related]
15. Concerns raised over declining antiinfectives R&D.
Fox JL
Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
[No Abstract] [Full Text] [Related]
16. Pipelines turn to biotech.
Lawrence S
Nat Biotechnol; 2007 Dec; 25(12):1342. PubMed ID: 18066015
[No Abstract] [Full Text] [Related]
17. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
Alifrangis C; Krell J; Stebbing J
Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231
[No Abstract] [Full Text] [Related]
18. [From a crisis to another...Pharmaceutical industry--economics].
Scheen AJ
Rev Med Liege; 2009 Jan; 64(1):3-5. PubMed ID: 19317093
[No Abstract] [Full Text] [Related]
19. Guidelines for measuring the costs and consequences of adopting new pharmaceutical products: are they on track?
Pausjenssen AM; Detsky AS
Med Decis Making; 1998; 18(2 Suppl):S19-22. PubMed ID: 9566463
[No Abstract] [Full Text] [Related]
20. Biopharmaceutical benchmarks 2006.
Walsh G
Nat Biotechnol; 2006 Jul; 24(7):769-76. PubMed ID: 16841057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
